Originally published Jan. 18.
EU's Committee for Medicinal Products for Human Use this week recommended that the European Medicine's Agency grant conditional marketing authorization for Pfizer's leukemia drug bosutinib.
The European Commission's Committee for Medicinal Products for Human Use last eek recommended marketing authorization for Roche's Zelboraf as a monotherapy for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.
Following a positive recommendation from the EMA committee, the European Commission is expected to issue a decision in September regarding marketing Tarceva as a first-line treatment for EGFR-mutation-positive NSCLC.
A Finnish government task force plans to release its final report on Aug. 31 after conducting further investigations into the epidemiologic, immunologic, and genetic causes for the onset of narcolepsy following vaccination with Pandemrix.